Intravenous Fluid Resuscitation in Acute Pancreatitis: Evidence-Based Treatment

Early intravenous fluid management is central to the treatment of acute pancreatitis. The approach depends on the patient's volume status at presentation and requires structured reassessment over the first 24–48 hours to guide ongoing resuscitation.

Clinical Treatment Targets

The primary goal of fluid therapy is a decrease in BUN and hemodilution (falling hematocrit), which reflect adequate renal perfusion and volume restoration. Fluid status is formally reassessed within 6 hours of presentation and monitored over the subsequent 24–48 hours.

Treatment Approach

Current evidence supports moderately aggressive intravenous resuscitation. A specific fluid solution is preferred over alternatives based on comparative clinical evidence. Resuscitation rate and bolus decisions are individualised according to the patient’s volume status at the time of presentation.

Full protocol — fluid selection, rate criteria, bolus thresholds, and monitoring targets — available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.14309/ajg.0000000000002645

We suggest moderately aggressive fluid resuscitation for patients with AP.
Additional boluses will be needed if there is evidence of hypovolemia.
We suggest using lactated Ringer solution over normal saline for intravenous resuscitation in AP.
From this study, we can conclude that in patients with no evidence of hypovolemia, an initial resuscitation rate of no more than 1.5 mL/kg of body weight per hour should be administered.
However, in patients with hypovolemia, clinicians should administer a bolus of 10 mL/kg.
While the presence of hypovolemia might demand higher amounts and rates of hydration, most patients with AP will likely benefit from 3-4 L the first 24 hours, depending on body mass index.
Fluid volumes need to be reassessed at frequent intervals within 6 hours of presentation and for the next 24-48 hours with a goal to decrease the BUN.
In general, intravenous hydration providing for a decrease in the HCT (hemodilution) and/or decreased BUN (increased renal perfusion) have been shown to be associated with decreased morbidity and mortality.

View source ↗